The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
In this webinar, Stefanie Müthel and Jessica Fiege will discuss how electroporation using the latest technology boosts cell ...
The non-viral transfection reagents market presents growth opportunities driven by the demand for cost-effective, low-immunogenicity alternatives to viral vectors, particularly for nucleic acid-based ...
Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of AAV production for gene therapies.
In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...
Lonza Group AG has broadened its suite of CGT manufacturing solutions with 2 new products: TheraPEAK AmpliCell Cytokines and ...
A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.
News-Medical.Net on MSN
PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies
PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback